In the present study, HFn NPs that have intrinsic BBB-crossing ability were engineered with a tumor penetration peptide RGE, termed RGE-HFn NPs, to facilitate delivery of the STING agonist SR717 into the brain tumor. This evidence concerns the gene STING1 and brain neoplasm.